Blood vs. CSF vs. PET Biomarkers: Which to Use for Brain Diseases and CNS Trials
Blood, cerebrospinal fluid (CSF), and PET biomarkers each measure brain disease in a different way: PET shows where pathology is in the brain, CSF gives a close chemical readout of the brain from a lumbar puncture, and blood tests are the easiest to repeat but measure brain signals that are diluted in circulation. Choosing between them depends on the question: diagnosis, trial enrollment, pharmacodynamics, or long-term monitoring. This explainer compares blood vs CSF vs PET biomarkers for neurodegenerative diseases and CNS clinical trials. This comparison highlights the differences between blood vs CSF vs PET biomarkers, emphasizing the importance of understanding blood vs CSF vs PET biomarkers and their roles in diagnosis and treatment.
Key takeaways
Understanding the distinctions between blood vs CSF vs PET biomarkers is crucial for accurate diagnosis and treatment planning in neurology.
When considering blood vs CSF vs PET biomarkers, it’s important to weigh their strengths and weaknesses in different clinical scenarios.
The ongoing discussion about blood vs CSF vs PET biomarkers continues to evolve as new research emerges.
Incorporating the analysis of blood vs CSF vs PET biomarkers into clinical practice can enhance patient outcomes.
In many studies, researchers have focused on the comparative efficacy of blood vs CSF vs PET biomarkers.
- PET visualizes amyloid or tau in the living brain and remains a reference for Alzheimer’s pathology, but it is expensive, uses radiation and is limited to specialized centers.
- CSF from a lumbar puncture measures Aβ42/40, phosphorylated tau, NfL and α-synuclein seeds close to the brain, but it is invasive and hard to repeat at every trial visit.
- Blood tests such as plasma pTau217 now approach CSF and PET accuracy for Alzheimer’s pathology in specialty care, and blood can be drawn at every visit.[1][2]
- Brain-specific signals in blood are the main challenge: many disease proteins are also made outside the brain. Neuron-derived extracellular vesicles (NDEs) are one way to recover a neuronal signal from blood.
As we analyze patient data, the significance of blood vs CSF vs PET biomarkers becomes increasingly evident.
PET imaging
Positron emission tomography (PET) uses radioactive tracers that bind specific pathology. Amyloid PET and tau PET (for example flortaucipir) show both whether pathology is present and where it is in the brain, which is why they support diagnosis, staging and trial enrollment in Alzheimer’s disease.[3][4] PET is expensive, involves radiation exposure, needs specialized centers and is impractical at frequent intervals. There is no established PET tracer for α-synuclein or TDP-43 in routine use.
Improved understanding of blood vs CSF vs PET biomarkers can guide treatment strategies for Alzheimer’s disease.
Ongoing advancements in research methods will contribute to the dialogue about blood vs CSF vs PET biomarkers.
In future guidelines, the delineation of blood vs CSF vs PET biomarkers will become even more crucial.
Clinical trials will benefit from a robust framework comparing blood vs CSF vs PET biomarkers.
Cerebrospinal fluid (CSF)
CSF bathes the brain and spinal cord, so proteins released by brain cells reach it at higher relative concentrations than in blood. Established CSF markers include Aβ42/40, phosphorylated tau and total tau for Alzheimer’s disease, NfL for neurodegeneration, and the α-synuclein seed amplification assay (SAA) for synuclein pathology, now a reference in Parkinson’s research.[5] The drawback is the lumbar puncture: it is invasive, some participants decline it, and repeat sampling across many trial visits is difficult.
Ultimately, the decision-making process regarding blood vs CSF vs PET biomarkers should be informed by the latest research findings.
Blood (plasma and serum)
Blood is easy to collect at every visit and at scale. In Alzheimer’s disease, plasma pTau217 distinguishes Alzheimer’s from other neurodegenerative disorders with high accuracy,[6] a plasma pTau217/Aβ42 ratio test was FDA-cleared in May 2025,[7] and the Alzheimer’s Association’s 2025 clinical practice guideline supports blood tests in specialty care for people with cognitive impairment: as a triage test when sensitivity is at least 90% and specificity at least 75%, and as a substitute for PET or CSF when both are at least 90%.[2]
Blood has two limits. Brain proteins are diluted in a large volume and some are degraded, and many disease proteins, such as α-synuclein, are abundant in blood cells, so plain plasma levels mostly reflect the periphery. Isolating neuron-derived extracellular vesicles first is one way to measure neuronal cargo from blood.
Understanding the nuances of blood vs CSF vs PET biomarkers can lead to better patient outcomes.
Blood vs. CSF vs. PET at a glance
As we continue to refine our strategies, the comparison of blood vs CSF vs PET biomarkers will be pivotal.
| Blood | CSF | PET | |
|---|---|---|---|
| How collected | Routine blood draw | Lumbar puncture | Tracer injection and scan |
| Invasiveness | Minimal | Invasive | Non-invasive, radiation exposure |
| Repeatable at every trial visit | Yes | Rarely | Rarely |
| Relative cost and access | Lowest, widely available | Moderate, needs trained clinicians | Highest, specialized centers |
| What it shows | Circulating proteins; neuronal cargo if NDEs are isolated | Brain-derived proteins and protein seeds | Location and burden of amyloid or tau |
| Main limitation | Dilution and non-brain sources | Burden of repeated punctures | Cost, radiation, limited tracers |
Which to use in a CNS clinical trial
This ongoing exploration of blood vs CSF vs PET biomarkers will foster advancements in neurodegenerative disease research.
Each method’s distinct approach to understanding neurodegenerative diseases makes the discussion of blood vs CSF vs PET biomarkers critical for future research.
- Screening and enrollment: blood tests can pre-screen large populations, with PET or CSF confirming eligibility where required. This reduces the number of costly or invasive procedures.
- Pharmacodynamics and target engagement: blood is the only matrix practical at every visit; CSF can confirm central effects at selected timepoints. See Pharmacodynamic biomarkers.
- Disease monitoring: serial blood NfL tracks neurodegeneration; PET can document changes in amyloid or tau burden over longer intervals.
- Safety: MRI, not PET, monitors amyloid-related imaging abnormalities (ARIA) with anti-amyloid antibodies.
Ultimately, the choice between blood vs CSF vs PET biomarkers should be guided by specific clinical needs.
More on this trade-off: CSF and the case for blood-based CNS biomarkers and Why CSF biomarkers break down in late-stage CNS trials.
How NeuroDex measures this
NeuroDex isolates neuron-derived extracellular vesicles from a routine EDTA plasma or serum sample (minimum 500 µL) with its ExoSORT™ platform, so neuronal α-synuclein, TDP-43, tau and signaling proteins can be measured from blood at every visit, without a lumbar puncture. Assays run in our CLIA-certified, GCLP-aligned laboratories.
ExoSORT™ platform · Applications by disease · Clinical trial services
Frequently asked questions
Is a blood test as accurate as PET for Alzheimer’s disease?
In specialty care, the best plasma pTau217 tests approach CSF and PET accuracy. The Alzheimer’s Association’s 2025 guideline supports blood tests with at least 90% sensitivity and specificity as a substitute for PET or CSF in people with cognitive impairment.
Why is CSF closer to the brain than blood?
CSF surrounds the brain and spinal cord, so proteins released by brain cells reach it at higher relative concentrations. In blood they are diluted and mixed with proteins from other tissues.
Can Parkinson’s disease be detected in blood?
Plain plasma α-synuclein is not reliable because blood cells contain large amounts of it. Research approaches include measuring α-synuclein in neuron-derived extracellular vesicles isolated from blood.
Which biomarker sample is best for a clinical trial?
It depends on the question. Blood suits screening and repeated pharmacodynamic sampling, CSF confirms central effects at selected visits, and PET documents the location and burden of pathology.
References
- Hansson O, et al. The Alzheimer’s Association appropriate use recommendations for blood biomarkers in Alzheimer’s disease. Alzheimers Dement. 2022;18(12):2669–2686. doi:10.1002/alz.12756
- Patient Care. Alzheimer’s Association releases first clinical guideline on use of blood-based biomarker tests. July 30, 2025.
- Jack CR Jr, et al. Revised criteria for diagnosis and staging of Alzheimer’s disease: Alzheimer’s Association Workgroup. Alzheimers Dement. 2024;20(8):5143–5169. doi:10.1002/alz.13859
- Ossenkoppele R, et al. Discriminative accuracy of [18F]flortaucipir positron emission tomography for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2018;320(11):1151–1162. doi:10.1001/jama.2018.12917
- Siderowf A, et al. Assessment of heterogeneity among participants in the Parkinson’s Progression Markers Initiative cohort using α-synuclein seed amplification. Lancet Neurol. 2023;22(5):407–417. doi:10.1016/S1474-4422(23)00109-6
- Palmqvist S, et al. Discriminative accuracy of plasma phospho-tau217 for Alzheimer disease vs other neurodegenerative disorders. JAMA. 2020;324(8):772–781. doi:10.1001/jama.2020.12134
- AJMC. FDA clears first blood test for early detection of Alzheimer-linked amyloid plaques. May 2025.
Related reading: What is a blood test for Alzheimer’s? · Types of biomarkers explained · Glossary of CNS biomarker terms
Leave a Reply